Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for CTX310 (ANGPTL3) in Atherosclerotic cardiovascular disease . The expected timing is based on the latest available company guidance and may change.
6/26/25- Reported add'l Ph1 data. 11/8/25- Late-breaking data presented at AHA'25. Advancing into Ph1b trials. 11/10/25:- Positive Phase 1 CTX310 data presented at the American Heart Association Scientific Sessions and published in The New England Journal of Medicine are reiterated, and the program is advancing into Phase 1b trials focused on severe hypertriglyceridemia and mixed dyslipidemia. 01/12/26:- CTX310 advanced into Ph1b for sHTG and refractory hypercholesterolemia; program update in H2 2026. 02/12/26:- CTX310 Phase 1b trials in sHTG and refractory hypercholesterolemia ongoing; program update still expected in H2 2026. 05/04/26:- CTX310 Ph1b sHTG/refractory hypercholesterolemia study expanding into US after IND clearance; program update still planned H2 2026. 08/03/26:- Ph1a ESC update Aug 28; Ph1b update still expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.